Haptocorrin-Bound Peptide Conjugates for Serum Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Peptide drugs face challenges such as instability in serum due to protease action, short half-life, and undesirable side effects like weight loss and central nervous system (CNS) effects, which limit their therapeutic effectiveness and safety.
Innovation Solution
Conjugating Exendin-4 with a haptocorrin binding substrate like vitamin B12 derivatives to increase its half-life, reduce CNS access, and minimize side effects by binding to unsaturated haptocorrin in the blood, thereby avoiding transcobalamin II binding and potential B12 deficiency.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide drugs are used to achieve therapeutic effects, then pharmacological activity is improved, but serum stability deteriorates due to protease degradation
Solution Approach 1:
The patent uses albumin binding proteins as intermediary carriers to transport the peptide drug through the bloodstream. The conjugate consists of a peptide drug moiety linked to an albumin binding protein moiety, which protects the peptide from protease degradation while maintaining its pharmacological activity at the target site.
Solution Approach 2:
The patent creates a composite conjugate structure combining two different molecular components: a peptide drug (e.g., Exendin-4) and an albumin binding protein (e.g., Haptocorrin or Transcobalamin I). This composite structure leverages the stability and long circulation half-life of albumin binding proteins while retaining the therapeutic activity of the peptide drug.
2Duration of action of moving object
If peptide drugs are conjugated to albumin binding proteins to extend half-life, then duration of action is improved, but drug efficacy deteriorates due to inhibited release
Solution Approach 1:
The patent designs a dynamic conjugate system where the peptide drug is temporarily bound to the albumin binding protein during circulation, then released at the target site. The conjugate maintains stability in the bloodstream but undergoes conformational changes or enzymatic cleavage at the destination, allowing the peptide to become active and bind to its receptor.
Solution Approach 2:
The patent divides the conjugate into functionally distinct segments: a peptide drug moiety responsible for pharmacological activity and an albumin binding protein moiety responsible for circulation stability. This segmentation allows each component to perform its specific function independently while being part of a unified therapeutic agent.
3Reliability
If potent peptide agonists are used to achieve strong pharmacological effects, then therapeutic effect is improved, but harmful side effects worsen due to CNS penetration
Solution Approach 1:
The patent uses the albumin binding protein conjugate as an intermediary delivery system that controls access of the peptide drug to the central nervous system. The large conjugate structure and albumin binding properties prevent or reduce CNS penetration, thereby blocking the pathway to harmful side effects while maintaining peripheral therapeutic effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The conjugation extends the half-life of Exendin-4, reduces CNS-related side effects like nausea and weight loss, while maintaining glucoregulatory effects without inducing vitamin B12 deficiency, as demonstrated by animal studies showing improved pharmacokinetics and reduced side effects.
Implementation Method 1
The conjugation to certain B 12 and/or related compounds allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The invention involves the coupling of compounds that can be bound by Haptocorrin (R-binder; Transcobalamin I; HC) to a target drug to improve pharmacokinetics, avoid undesirable side effects, and/or modify CNS access and localization. The pharmaceutical effect may be improved by conjugating the drug to haptocorrin binding substrate. This allows the conjugate to become bound to unsaturated haptocorrin in the blood, thereby protecting the drug from metabolism or excretion to increase protein half-life while not interfering with the efficacy of the protein drug. The conjugation may additionally prevent the drug from reaching the central nervous system or modify where the drug localizes and produces undesirable side effects such as nausea or hypophagia. Such a route also would prevent, in all case save for actual vitamin B12, binding by serum transcobalamin II (TCII), and thus not cause B12 deficiency with long term use.